search
Back to results

Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain

Primary Purpose

Temporomandibular Joint Disorder

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Neurovit Forte
Corn Starch
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Temporomandibular Joint Disorder focused on measuring Vitamin B, Temporomandibular joint disorder, trpv1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • minimum age of 18
  • temporomandibular joint disorder with pain
  • chronic condition- symptoms lasting more than 3 months with at least 2 episodes of pain in last 1 month
  • language competence- in Cantonese or English
  • all ethnicity

Exclusion Criteria:

  • ankylosis of the joint
  • limited mental capacity
  • pregnancy and lactating mothers
  • inability to take medications (NSAIDS-Ibuprofen or Vitamin B)
  • undergoing concurrent pharmacotherapy with anti inflammatory or muscle relaxant medications
  • poor general health
  • history of TMJ trauma or TMJ surgery
  • subjects taking Vitamin B for other uses

Sites / Locations

  • Prince Philip Dental Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Interventional

Placebo

Arm Description

Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks

Capsule containing 250mg corn starch

Outcomes

Primary Outcome Measures

Visual Analog Scale(VAS) Pain Score
assessment of pain level with VAS score at baseline (week 0)
Visual Analog Scale(VAS) Pain Score
assessment of pain level with VAS score at week2
Visual Analog Scale(VAS) Pain Score
assessment of pain level with VAS score at week4
Visual Analog Scale(VAS) Pain Score
assessment of pain level with VAS score at week6

Secondary Outcome Measures

mouth opening measurement in millimeter (mm)
assessment of mouth opening in millimeter (mm) at baseline (week0)
mouth opening measurement in millimeter (mm)
assessment of mouth opening in millimeter (mm) at week 2
mouth opening measurement in millimeter (mm)
assessment of mouth opening in millimeter (mm) at week 4
mouth opening measurement in millimeter (mm)
assessment of mouth opening in millimeter (mm) at week 6
number of participants with treatment related adverse events as assessed by CTCAE v4.03
Subjects will be assessed for any adverse events related to intervention , by using CYCAE v4.03, at week 0, week 2, week 4 and week 6
tablet count measurements to check complaince
remaining tablets will be counted at end of Week 6 to check compliance rate towards treatment

Full Information

First Posted
May 30, 2016
Last Updated
May 1, 2018
Sponsor
The University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT02794922
Brief Title
Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain
Official Title
Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine effectiveness of vitamin B in reducing temporomandibular joint disorder (TMD) pain. Patients will be randomised to receive the study drug or placebo. The study drug we are using is a combination of vitamin B1(thiamine mononitrate)-242.5mg; vitamin B6(pyridoxineHCl)-250mg, and vitamin B12(cyanocobalamin)-1mg. We will assess patient's pain level, range of jaw movement and record any side effects from using this medication.
Detailed Description
Type of study : Prospective double blinded randomized control trial Sample population : patients with temporomandibular joint disorder pain who are currently undergoing treatment in Oral & Maxillofacial surgery unit, Prince Philip Dental Hospital Study Period : 2 year (1st may2015 to 1st may 2017) Data Collection All new cases or existing TMD patients treated in oral maxillofacial surgery department, Prince Philip Dental Hospital will be acquired and screened based on inclusion and exclusion criteria. Selected patients will be categorised based on TMD axis 1 diagnosis and divided into two groups - group 1(Vitamin B) and group 2(placebo) randomly . Allocation of patients into the group will be based on computer generated by random block sequence. Complete social demographic background of the patient will recorded according to the following format age, gender, race, education, and job. Clinical assessment will be done to check 1. Mouth opening 2. Lateral excursion (right and left) 3. Protrusion 4. Deviation of lower jaw on opening 5. Tenderness of muscle of mastication 6. Pain - based on 10cm visual analog score. After initial assessments, patients will be started on either vitamin B complex or placebo based on their group. Both group of patients will be also prescribed with Tab Ibuprofen 400mg to be taken during acute Temporomandibular joint (TMJ) pain symptoms. These patients will be reviewed on week 0,2,4 and 6. All the patients will be reviewed by blinded assessor. Each patient will be given a log book to document frequency of TMJ pain attack, maximum pain score on each attack and amount of analgesics (Ibuprofen 400mg tabs) taken. Log book record will be checked on their review. Amount of analgesics recorded in log book and compliance of Vitamin B or placebo will be cross checked with remaining tablet count. Data Evaluation/ Statistical Analyses The statistical analysis of this study will use the standard version of Statistical Package for the Social Sciences (SPSS) version 17.0 for windows. All the data will be gathered and entered in into this software.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Temporomandibular Joint Disorder
Keywords
Vitamin B, Temporomandibular joint disorder, trpv1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Interventional
Arm Type
Experimental
Arm Description
Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Capsule containing 250mg corn starch
Intervention Type
Drug
Intervention Name(s)
Neurovit Forte
Other Intervention Name(s)
Vitamin B Complex
Intervention Type
Drug
Intervention Name(s)
Corn Starch
Primary Outcome Measure Information:
Title
Visual Analog Scale(VAS) Pain Score
Description
assessment of pain level with VAS score at baseline (week 0)
Time Frame
baseline
Title
Visual Analog Scale(VAS) Pain Score
Description
assessment of pain level with VAS score at week2
Time Frame
week 2
Title
Visual Analog Scale(VAS) Pain Score
Description
assessment of pain level with VAS score at week4
Time Frame
week 4
Title
Visual Analog Scale(VAS) Pain Score
Description
assessment of pain level with VAS score at week6
Time Frame
week 6
Secondary Outcome Measure Information:
Title
mouth opening measurement in millimeter (mm)
Description
assessment of mouth opening in millimeter (mm) at baseline (week0)
Time Frame
baseline
Title
mouth opening measurement in millimeter (mm)
Description
assessment of mouth opening in millimeter (mm) at week 2
Time Frame
week 2
Title
mouth opening measurement in millimeter (mm)
Description
assessment of mouth opening in millimeter (mm) at week 4
Time Frame
week4
Title
mouth opening measurement in millimeter (mm)
Description
assessment of mouth opening in millimeter (mm) at week 6
Time Frame
week 6
Title
number of participants with treatment related adverse events as assessed by CTCAE v4.03
Description
Subjects will be assessed for any adverse events related to intervention , by using CYCAE v4.03, at week 0, week 2, week 4 and week 6
Time Frame
6 weeks
Title
tablet count measurements to check complaince
Description
remaining tablets will be counted at end of Week 6 to check compliance rate towards treatment
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: minimum age of 18 temporomandibular joint disorder with pain chronic condition- symptoms lasting more than 3 months with at least 2 episodes of pain in last 1 month language competence- in Cantonese or English all ethnicity Exclusion Criteria: ankylosis of the joint limited mental capacity pregnancy and lactating mothers inability to take medications (NSAIDS-Ibuprofen or Vitamin B) undergoing concurrent pharmacotherapy with anti inflammatory or muscle relaxant medications poor general health history of TMJ trauma or TMJ surgery subjects taking Vitamin B for other uses
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Winnie Wing Shan Choi, BDS, MDS
Organizational Affiliation
Faculty of Dentistry, The University of Hong Kong
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jothi R Rajaran, DDS
Organizational Affiliation
Faculty of Dentistry, The University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Prince Philip Dental Hospital
City
Hong Kong
Country
China

12. IPD Sharing Statement

Learn more about this trial

Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain

We'll reach out to this number within 24 hrs